Skip to main content
Top
Published in: Rheumatology International 11/2020

01-11-2020 | Ankylosing Spondylitis | Observational Research

A prospective study of novel disease activity indices for ankylosing spondylitis

Authors: T. G. Sundaram, Hafis Muhammed, Amita Aggarwal, Latika Gupta

Published in: Rheumatology International | Issue 11/2020

Login to get access

Abstract

There is an ongoing quest for robust disease activity measures in Ankylosing spondylitis (AS). Thus, we prospectively validated two new disease activity indices, Simplified AS Disease Activity Score (SASDAS) and modified Juvenile Spondyloarthritis Disease Activity Score (JSpADA). Patients with AS were assessed for BASDAI, ASDAS and other outcome measures at baseline and 3 months. Comparisons were drawn between those with juvenile onset, early disease and peripheral involvement, with the rest. Fisher’s r to Z transformation was used to compare correlations. Receiver-operating characteristic (ROC) curves were used to calculate cutoffs for inactive, low, high and very high disease activity. Of the 107 patients (mean age—29 years) of 6-years long disease, 38.3% had a juvenile onset. SASDAS and modified JSpADA exhibited excellent correlation with BASDAI and ASDAS (all p < 0.001) and were higher in active vs. inactive disease. Treatment responders had a greater fall in SASDAS and modified JSpADA as compared to non-responders. The novel scores were higher in those with peripheral disease. Only SASDAS could discriminate early from late disease. Based on the previously proposed cutoffs, optimal scores for inactive, moderate, high and very high disease activity were deduced. SASDAS-CRP showed better internal consistency than SASDAS-ESR and correlated better with ASDAS-CRP in late disease (Z = 3.04; p = 002) and those with adult onset disease (Z = 2.18; p = 0.03). SASDAS and Modified JSpADA perform as well as standard complex scores and have potential for simpler daily use. From our analyses, SASDAS with CRP performs better than SASDAS-ESR, pending further validation.
Appendix
Available only for authorised users
Literature
2.
go back to reference Flatø B, Hoffmann-Vold AM, Reiff A, Førre Ø, Lien G, Vinje O (2006) Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 54:3573–3582CrossRef Flatø B, Hoffmann-Vold AM, Reiff A, Førre Ø, Lien G, Vinje O (2006) Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 54:3573–3582CrossRef
4.
go back to reference Gupta L, Bhattacharya S, Agarwal V, Aggarwal A (2016) Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol 35:3075–3079CrossRef Gupta L, Bhattacharya S, Agarwal V, Aggarwal A (2016) Elevated levels of serum MRP8/14 in ankylosing spondylitis: associated with peripheral arthritis and active disease. Clin Rheumatol 35:3075–3079CrossRef
8.
go back to reference Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA (2012) CARRA Registry Investigators Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 39:2341–2351CrossRef Weiss PF, Beukelman T, Schanberg LE, Kimura Y, Colbert RA (2012) CARRA Registry Investigators Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J Rheumatol 39:2341–2351CrossRef
10.
go back to reference Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D (2004) The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 51:154–159CrossRef Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D (2004) The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum 51:154–159CrossRef
11.
go back to reference Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Diss 68:18–24CrossRef Lukas C, Landewé R, Sieper J et al (2009) Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Diss 68:18–24CrossRef
12.
go back to reference Aranda-Valera IC, Garrido-Castro JL, Ladehesa-Pineda L, Vazquez-Mellado J, Zarco P, Juanola X, Gonzalez-Navas C, Font-Ugalde P, Castro-Villegas MC (2019) How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI- based ASDAS formula. Rheumatology. https://doi.org/10.1093/rheumatology/kez480CrossRef Aranda-Valera IC, Garrido-Castro JL, Ladehesa-Pineda L, Vazquez-Mellado J, Zarco P, Juanola X, Gonzalez-Navas C, Font-Ugalde P, Castro-Villegas MC (2019) How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI- based ASDAS formula. Rheumatology. https://​doi.​org/​10.​1093/​rheumatology/​kez480CrossRef
15.
18.
19.
23.
go back to reference Bakker C, Boers M, van der Linden S (1993) Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. J Rheumatol 20:1724–1730PubMed Bakker C, Boers M, van der Linden S (1993) Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. J Rheumatol 20:1724–1730PubMed
24.
go back to reference Brandt J, Westhoff G, Rudwaleit M et al (2003) Validierung einer deutschen Version des Fragebogens BASDAI zur Messung der Krankheitsaktivität bei ankylosierender Spondylitis [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Z Rheumatol 62:264–273. https://doi.org/10.1007/s00393-003-0522-yCrossRefPubMed Brandt J, Westhoff G, Rudwaleit M et al (2003) Validierung einer deutschen Version des Fragebogens BASDAI zur Messung der Krankheitsaktivität bei ankylosierender Spondylitis [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]. Z Rheumatol 62:264–273. https://​doi.​org/​10.​1007/​s00393-003-0522-yCrossRefPubMed
28.
go back to reference Bennett AN, McGonagle D, O'Connor P et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58:3413–3418. https://doi.org/10.1002/art.24024CrossRefPubMed Bennett AN, McGonagle D, O'Connor P et al (2008) Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 58:3413–3418. https://​doi.​org/​10.​1002/​art.​24024CrossRefPubMed
Metadata
Title
A prospective study of novel disease activity indices for ankylosing spondylitis
Authors
T. G. Sundaram
Hafis Muhammed
Amita Aggarwal
Latika Gupta
Publication date
01-11-2020
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 11/2020
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-020-04662-w

Other articles of this Issue 11/2020

Rheumatology International 11/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.